Thromboelastographic Results and Hypercoagulability Syndrome in Patients With Coronavirus Disease 2019 Who Are Critically Ill

JAMA Netw Open. 2020 Jun 1;3(6):e2011192

Our findings suggest that alterations of diagnostic and prophylactic treatment guidelines may be critical for the successful treatment of coagulopathies associated with COVID-19.

AddThis Sharing Buttons

Severe acute respiratory syndrome coronavirus 2 (SAR-CoV-2) is responsible for the coronavirus disease 2019 (COVID-19) pandemic that has caused approximately 300 000 deaths globally. Disseminated intravascular coagulopathy and other COVID-19–associated coagulopathies occur among patients with severe SARS-CoV-2 infections. Potentially lethal hypercoagulability is an unusual, poorly defined COVID-19–associated coagulopathy presentation. We found that more than half of patients admitted to the intensive care unit (ICU) of Baylor St Luke’s Medical Center developed clinically significant thromboses that were associated with hypercoagulable thromboelastographic (TEG) parameters alone.

Our findings suggest that alterations of diagnostic and prophylactic treatment guidelines may be critical for the successful treatment of coagulopathies associated with COVID-19.